HCG vs HMG
Human chorionic gonadotropin is a placental glycoprotein hormone that signals through the luteinizing hormone/chorionic gonadotropin receptor, reproducing LH activity with a much longer circulating half-life. Human menopausal gonadotropin, or menotropins, is a urinary-derived preparation carrying both follicle-stimulating hormone and luteinizing hormone activity, the latter contributed substantially by chorionic gonadotropin retained during purification. They are constantly set side by side because both are gonadotropin preparations used in fertility medicine, but in most protocols they are not alternatives to each other: hCG supplies LH-like drive while hMG supplies the FSH component that hCG lacks. Unusually for this library, direct comparative evidence does exist, in the form of meta-analyses of hCG given alone against hCG combined with hMG or recombinant FSH for spermatogenesis induction. Those syntheses pool largely non-randomised cohorts with substantial heterogeneity, which limits how firmly their conclusions can be read.
They have been compared directly.
The direct evidence takes the form of monotherapy-versus-combination comparisons rather than a contest between the two preparations. Pozzi and colleagues pooled 1240 men with congenital hypogonadotropic hypogonadism and reported a weighted mean time to recovery of spermatogenesis of 10 months with combination therapy against 33 months with hCG monotherapy, and sperm recovery rates of 66.76% against 51.9%; heterogeneity was high in both groups, at I-squared of 86% and 68% respectively, and the authors urged caution in interpreting the result. Shoaib and colleagues reviewed hCG monotherapy alongside hCG combined with FSH, hMG or selective oestrogen receptor modulators in male infertility and found the study designs heterogeneous and largely non-randomised. Alexander and colleagues reached a similar structural conclusion for pubertal induction, reporting that regimens were highly heterogeneous and randomised comparisons were largely absent. On the female side no comparable head-to-head exists, because there hMG is benchmarked against recombinant FSH rather than against hCG, and hCG appears as a trigger agent rather than as a stimulation drug.
The 3 studies that tested both
- 01Systematic review2025
Evaluating Sperm Recovery Time and Efficacy of Monotherapy vs. Combination Therapies in Men with Congenital Hypogonadotropic Hypogonadism: A Systematic Review and Meta-Analysis
Pozzi E, et al. · The World Journal of Men's Health · PRISMA systematic review and meta-analysis (PROSPERO CRD42023473615) of studies in azoospermic men with congenital hypogonadotropic hypogonadism receiving hCG monotherapy or hCG combined with human menopausal gonadotropin or recombinant FSH; 1240 men pooled, search to November 2023
Weighted mean time to recover spermatogenesis was 10 months with combination therapy versus 33 months with hCG monotherapy, and sperm recovery rates were 66.76% versus 51.9% (p=0.03). Heterogeneity was substantial in both arms (I-squared 86% for combination, 68% for monotherapy), and the authors stated that this variability warranted further investigation and caution in interpreting the results.
- 02Systematic review2025
Use of Human Chorionic Gonadotropin (HCG) or HCG-Combined Treatments in Male Infertility: A Systematic Review
Shoaib H, Duffy J, Ahmed K · Cureus · systematic review of hCG monotherapy and hCG-combination regimens in male infertility, including hCG combined with FSH, hMG or selective oestrogen receptor modulators, and use in men with prior exogenous androgen exposure
Semen-parameter and hormonal outcomes were summarised across monotherapy and combination regimens. Study designs were heterogeneous and largely non-randomised, which the review identified as the principal constraint on drawing comparative conclusions.
- 03Systematic review2024
Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis
Alexander EC, et al. · European Journal of Endocrinology · systematic review and meta-analysis of gonadotropin regimens, including hCG plus hMG or FSH, for pubertal induction in adolescent and young adult males with hypogonadotropic hypogonadism
Gonadotropin regimens increased testicular volume and induced pubertal development, but protocols were highly heterogeneous and randomised comparisons between regimens were largely absent.
Side by side.
| HCG | HMG | |
|---|---|---|
| Evidence maturity | Approved drug | Approved drug |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 12 | 11 |
| Newest paper | 2026 | 2026 |
| What the preparation contains | A heterodimeric placental glycoprotein sharing an alpha subunit with LH, FSH and TSH. Available as urinary-derived hCG and as recombinant choriogonadotropin alfa. It carries LH-like activity only. | A urinary-derived preparation carrying both follicle-stimulating hormone and luteinizing hormone activity, the LH component contributed substantially by chorionic gonadotropin retained during purification. Highly purified formulations are designated hp-hMG. |
| Receptor target | The luteinizing hormone/chorionic gonadotropin receptor (LHCGR), driving Leydig-cell testosterone production in men and final oocyte maturation in women. Knockout work in LHCGR-null mice delineates the pathway. | The FSH receptor on granulosa and Sertoli cells for the FSH component, with additional LHCGR engagement from the LH activity, so a single preparation reaches both arms of the gonadotropin axis. |
| Whether they substitute or combine | In male hypogonadotropic hypogonadism hCG is the base agent, given alone or as the foundation for combination. In assisted reproduction it functions as a trigger for final oocyte maturation rather than as a stimulation drug. | Used as the stimulation agent in ovarian stimulation, and in men as the added FSH-activity component on top of hCG. It is rarely positioned as a replacement for hCG in either setting. |
| What the direct comparison actually tested | hCG alone as the comparator arm: pooled sperm recovery of 51.9% with a weighted mean recovery time of 33 months across 1240 men with congenital hypogonadotropic hypogonadism. | hMG appears inside the combination arm rather than as an isolated comparator, pooled together with recombinant FSH: 66.76% recovery with a weighted mean of 10 months, so the meta-analysis cannot separate hMG from rFSH as the added component. |
| Strongest evidence on the female side | Randomised trials and network meta-analyses of trigger strategy, comparing hCG with GnRH agonist and dual triggers; recent syntheses report limited certainty for differences in live birth between trigger agents, and a Cochrane review of insemination timing found no clear advantage for any single strategy. | A large randomised literature benchmarking hp-hMG against recombinant FSH. A 2026 Cochrane update reported that live birth and clinical pregnancy were probably lower with rFSH than with hMG or hp-hMG and that ovarian hyperstimulation syndrome was probably higher with rFSH, at moderate certainty, while other syntheses found comparable live birth with differing oocyte yields. |
| Quality of the male-fertility evidence | Mostly uncontrolled cohorts in congenital or acquired gonadotropin deficiency. A multicentre randomised trial in idiopathic hypogonadal non-obstructive azoospermia has been reported, but most data on spermatogenesis induction are non-randomised. | Weaker still as a standalone question. The syntheses covering hMG in male hypogonadotropic hypogonadism describe small, heterogeneous and largely non-randomised studies with no consensus on LH-activity dosing. |
| Claims outside fertility | A criteria-based meta-analysis of controlled trials found hCG no more effective than placebo for weight loss, fat redistribution, hunger or wellbeing on a very-low-calorie diet, and concluded there was no scientific evidence supporting hCG in obesity. | No comparable body of weight-loss claims or refuting trials exists; the literature stays within reproductive endocrinology. |
And what it does not.
This is one of the few pairings in this library where direct comparative evidence exists, and it points in a consistent direction: pooled across 1240 men with congenital hypogonadotropic hypogonadism, combination gonadotropin therapy was associated with faster and more frequent sperm recovery than hCG alone. Three qualifications sit on top of that. Heterogeneity was high, at I-squared of 86% and 68%, and the meta-analysis authors themselves urged caution. The combination arm pooled hMG with recombinant FSH, so the analysis does not isolate hMG as the added component. And the underlying studies were largely non-randomised cohorts, a limitation that recurs in every synthesis of gonadotropin therapy for male fertility. Away from that question the two preparations are not really rivals: on the female side hMG is compared with recombinant FSH rather than with hCG, hCG serves as a trigger rather than a stimulation drug, and recent network meta-analyses report limited certainty for differences in live birth between trigger agents. Neither preparation has controlled support for any use outside reproductive endocrinology, and controlled trials specifically found hCG no better than placebo for weight loss.
Common questions.
- Are hCG and hMG alternatives to each other, or are they used together?
In the published protocols they are mostly used together rather than as substitutes. hCG supplies luteinizing hormone activity through the LHCGR, and hMG supplies the follicle-stimulating hormone activity that hCG lacks. The direct evidence in male hypogonadotropic hypogonadism is structured as hCG alone versus hCG plus an FSH-activity preparation, not as one preparation against the other.
- What did the meta-analysis of gonadotropin monotherapy versus combination therapy report?
Pooling 1240 men with congenital hypogonadotropic hypogonadism, weighted mean time to recovery of spermatogenesis was 10 months with combination therapy against 33 months with hCG monotherapy, and sperm recovery rates were 66.76% against 51.9%. Heterogeneity was substantial in both groups, and the authors stated that the variability in individual responses warranted caution in interpreting the results.
- Which of the two preparations carries follicle-stimulating hormone activity?
Human menopausal gonadotropin does. It is a urinary-derived preparation containing both FSH and LH activity, with the LH component contributed substantially by chorionic gonadotropin retained during purification. Human chorionic gonadotropin carries LH-like activity only, acting through the luteinizing hormone/chorionic gonadotropin receptor.
- Does the direct evidence show that hMG specifically adds the benefit?
It does not separate that out. In the meta-analysis the combination arm pooled hCG plus human menopausal gonadotropin together with hCG plus recombinant FSH, so the analysis measures the effect of adding FSH activity rather than the effect of hMG in particular. No pooled comparison of hMG against recombinant FSH as the added component in male hypogonadotropic hypogonadism was located.
- How does hMG compare with recombinant FSH in assisted reproduction?
That comparison, rather than any comparison with hCG, is where the large randomised literature sits. A 2026 Cochrane update reported that live birth and clinical pregnancy were probably lower with recombinant FSH than with hMG or highly purified hMG, and that ovarian hyperstimulation syndrome was probably higher with rFSH, with moderate certainty. Other recent syntheses found comparable live birth alongside differing oocyte yields.
- Is there controlled evidence for either preparation outside fertility medicine?
No. A criteria-based meta-analysis of controlled trials of hCG in obesity found it no more effective than placebo for weight loss, fat redistribution, hunger or wellbeing when combined with a very-low-calorie diet, and concluded there was no scientific evidence supporting that use. The hMG literature does not extend beyond reproductive endocrinology at all.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.